Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors.

Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y, Tisza A, Marton T, Kovacs I, Tovari J, Laszlo V, Helbich TH, Hegedus B, Klikovits T, Hoda MA, Klepetko W, Paku S, Marko-Varga G, Dome B.

Theranostics. 2017 Jan 1;7(2):400-412. doi: 10.7150/thno.16767.

2.

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR.

J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845.

3.

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.

Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan MR, Wotherspoon A, Gao ZH, Shi Y, Van den Eynden G, Daley F, Peckitt C, Tan X, Salman A, Lazaris A, Gazinska P, Berg TJ, Eltahir Z, Ritsma L, van Rheenen J, Khashper A, Brown G, Nyström H, Sund M, Van Laere S, Loyer E, Dirix L, Cunningham D, Metrakos P, Reynolds AR.

Nat Med. 2016 Nov;22(11):1294-1302. doi: 10.1038/nm.4197.

PMID:
27748747
4.

Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.

Pinto MP, Sotomayor P, Carrasco-Avino G, Corvalan AH, Owen GI.

Int J Mol Sci. 2016 Sep 6;17(9). pii: E1489. doi: 10.3390/ijms17091489. Review.

5.

Glioblastoma: Defining Tumor Niches.

Hambardzumyan D, Bergers G.

Trends Cancer. 2015 Dec;1(4):252-265.

6.

FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.

Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

J Clin Invest. 2016 May 2;126(5):1885-96. doi: 10.1172/JCI85086.

7.

Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways.

Bentolila LA, Prakash R, Mihic-Probst D, Wadehra M, Kleinman HK, Carmichael TS, Péault B, Barnhill RL, Lugassy C.

Sci Rep. 2016 Apr 6;6:23834. doi: 10.1038/srep23834.

8.

Twenty years after: the beautiful hypothesis and the ugly facts.

Pezzella F, Gatter K, Qian CN.

Chin J Cancer. 2016 Feb 24;35:22. doi: 10.1186/s40880-016-0087-1.

9.

Morphological Changes of Cortical and Hippocampal Neurons after Treatment with VEGF and Bevacizumab.

Latzer P, Schlegel U, Theiss C.

CNS Neurosci Ther. 2016 Jun;22(6):440-50. doi: 10.1111/cns.12516.

10.

Sequence of treatment in locally advanced and metastatic renal cell carcinoma.

Fischer S, Gillessen S, Rothermundt C.

Transl Androl Urol. 2015 Jun;4(3):310-25. doi: 10.3978/j.issn.2223-4683.2015.04.07. Review.

11.

Pharmacologic resistance in colorectal cancer: a review.

Hammond WA, Swaika A, Mody K.

Ther Adv Med Oncol. 2016 Jan;8(1):57-84. doi: 10.1177/1758834015614530. Review.

12.

Prediction of anti-angiogenesis escape.

Mitamura T, Gourley C, Sood AK.

Gynecol Oncol. 2016 Apr;141(1):80-5. doi: 10.1016/j.ygyno.2015.12.033. Review.

PMID:
26748214
13.

Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.

Renner DN, Malo CS, Jin F, Parney IF, Pavelko KD, Johnson AJ.

Neurotherapeutics. 2016 Jan;13(1):226-36. doi: 10.1007/s13311-015-0407-1.

14.

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Niyazi M, Harter PN, Hattingen E, Rottler M, von Baumgarten L, Proescholdt M, Belka C, Lauber K, Mittelbronn M.

Oncotarget. 2016 Jan 19;7(3):2313-28. doi: 10.18632/oncotarget.6320. Review.

15.

Current status and future directions of anti-angiogenic therapy for gliomas.

Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, Winkler F.

Neuro Oncol. 2016 Mar;18(3):315-28. doi: 10.1093/neuonc/nov180. Review.

16.

Characterization of highly proliferative secondary tumor clusters along host blood vessels in malignant glioma.

Wang TC, Cheng CY, Yang WH, Chen WC, Chang PJ.

Mol Med Rep. 2015 Nov;12(5):6435-44. doi: 10.3892/mmr.2015.4228.

18.

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.

Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S.

Neuro Oncol. 2015 Oct;17(10):1386-92. doi: 10.1093/neuonc/nov085.

19.

Adaptation to antiangiogenic therapy in neurological tumors.

Flanigan PM, Aghi MK.

Cell Mol Life Sci. 2015 Aug;72(16):3069-82. doi: 10.1007/s00018-015-1916-0. Review.

20.

Tumor microenvironment: a new treatment target for cancer.

Tsai MJ, Chang WA, Huang MS, Kuo PL.

ISRN Biochem. 2014 Apr 10;2014:351959. doi: 10.1155/2014/351959. Review.

Supplemental Content

Support Center